Exploratory secondary analysis of a trial in metastatic kidney cancer (123 ccRCC, 31 pRCC): median KIM-1 was higher in pRCC (7835 vs 5470 pg/ml, p=0.05); in ccRCC high baseline KIM-1 was associated with shorter OS (HR 1.77).
Secondary analysisn = 154 patients
Coca Membribes et al. KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma